The case and the decision

A man has recurrent unprovoked venous thrombosis, relatives with low factor II clotting activity but normal antigen, and a prolonged thrombin-generation tail. Reciprocal replacement experiments make that curve follow the patient-derived factor II preparation. No coding variant has been identified, and the preparation contains unseparated molecular species.

Where MontMedical gives the stronger account

OpenEvidence favours antithrombin-resistant dysprothrombinemia, a coherent leading mechanism. It then assigns the transfer to the prothrombin molecule itself and treats the long tail as the characteristic inhibition defect. MontMedical keeps the strong familial diagnosis while identifying what the experiment actually transfers: the patient-derived preparation.

A preparation-level result is valuable localisation. A sequence-defined protein comparison would determine whether a particular variant reproduces it. That is a more precise next step than treating molecular causation as already demonstrated.

Why the distinction matters

Small peptides can be cleaved by alpha-2-macroglobulin-bound thrombin even when its action on large clotting substrates is restricted. A second small peptide corroborates cleavage; it does not independently establish late fibrinogen clotting. Published assay work supports that distinction. [1]

Likewise, lower complex-immunoassay signal can reflect less enzyme generated, altered recognition or impaired complex formation. Matched starting active enzyme, separated activation and inhibition, and an independent complex readout would test the inhibition claim directly.

What OpenEvidence gets right

It identifies an important, published mechanism and explains why a negative G20210A test does not cover coding variants. Its sequencing and family-assessment discussion is practical. The original Yukuhashi study did demonstrate resistance using a characterised variant; that provides precedent, rather than confirmation of the teaching case's unsequenced protein. [2]

Our preference here concerns the experiment-to-mechanism inference, not a claim that OpenEvidence missed the leading disorder.